Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Mitsubishi Makes Major Investment In Chinese Biotechs

This article was originally published in PharmAsia News

Executive Summary

Mitsubishi announced plans to back biotech startups in China, beginning with a $3 million investment in a venture fund. The Shanghai-based fund, BioVeda China Fund II LP, invests in several biotech fields, including pharmaceuticals. Similar investments from Eli Lilly and a World Bank group, among other American and European infusions, contribute to the fund's hope to raise more than $100 million. Mitsubishi said it chose the fund because of China's growing status as a base for research and development and as a drug market. The firm said it might seek some marketing rights in Japan if the investments lead to lucrative drugs. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts